We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mettler-Toledo Stock Up on Q3 Earnings & Revenue Beat, '26 View Up
Read MoreHide Full Article
Key Takeaways
MTD's Q3 earnings rose 13% to $12.57 per share, while sales climbed 6% to $1.09 billion, beating estimates.
MTD's Asia/Rest of World sales surged 16%, while adjusted operating margin expanded 40 basis points.
MTD raises 2026 EPS guidance to $47.70-$47.90 and projects 2027 earnings of $52.50-$53.50 per share.
Mettler-Toledo International (MTD - Free Report) reported third-quarter 2026 adjusted earnings of $12.57 per share, which beat the Zacks Consensus Estimate by 3.8%. Adjusted earnings increased 13% from $11.15 per share a year ago.
Net sales of $1.09 billion increased 6% year over year and surpassed the Zacks Consensus Estimate by 2.3%. Improving market demand, particularly in Asia/Rest of World, supported the quarterly performance. Organic local-currency sales increased 6%, reflecting relatively broad-based growth across the company's portfolio.
Following the earnings announcement, MTD stock rose 0.1% in after-market trading yesterday.
MTD Benefits From Strong Regional Sales Momentum
On a local-currency basis, MTD's sales increased 3% in the Americas, 2% in Europe and 14% in Asia/Rest of World during the third quarter. The strong performance in Asia/Rest of World was a key contributor to overall sales growth.
On a reported basis, Americas sales increased 3% year over year, while European sales remained flat. Asia/Rest of World sales climbed 16%, highlighting the region's contribution to the company's revenue expansion.
Excluding acquisitions, organic local-currency sales increased 6% during the quarter. Organic sales growth reached 3% in the Americas and 13% in Asia/Rest of World, indicating that underlying demand supported growth beyond acquisition contributions.
MTD Expands Profitability Despite Higher Expenses
Gross profit increased to $654.22 million from $609.46 million in the prior-year quarter. Gross margin expanded 60 basis points year over year to 59.8%, reflecting improved profitability.
Research and development expenses increased to $53.61 million from $51.14 million. Selling, general and administrative expenses rose to $267.16 million from $248.39 million. Meanwhile, amortization expenses declined to $19.37 million from $20.02 million.
Adjusted operating profit increased 8% year over year to $333.45 million. Adjusted operating margin expanded 40 basis points to 30.5%, demonstrating improved operating efficiency despite higher expenses.
As of Sept. 30, 2026, cash and cash equivalents were $52.24 million compared with $ $51.4 million as of June 30, 2025. Long-term debt declined to $1.96 billion from $2.09 billion over the same period.
Mettler-Toledo generated $308.57 million in operating cash flow during the third quarter, compared with $299.37 million in the year-ago period. Adjusted free cash flow increased to $285.15 million from $280.73 million.
Mettler-Toledo Raises 2026 Outlook and Issues 2027 Guidance
For 2026, Mettler-Toledo raised its adjusted earnings guidance to $47.70-$47.90 per share from $47.15-$47.50. The updated outlook implies earnings growth of approximately 12%. The Zacks Consensus Estimate for the metric is pegged at $47.38, implying 11% year-over-year growth.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
The company now anticipates full-year local-currency sales growth of approximately 5%, excluding customer tariff refunds, compared with its earlier projection of 4-5%. The Zacks Consensus Estimate is pegged at $4.23 billion, implying 8.6% growth from 2025.
Management expects local-currency sales to increase approximately 5% in 2027. Adjusted earnings are projected to be between $52.50 and $53.50 per share, implying growth of approximately 10-12%. Per the Zacks Consensus Estimate, 2027 sales and EPS are projected to be $4.43 billion and $52.37, respectively.
Our Take
Mettler-Toledo posted better-than-expected third-quarter results, wherein both earnings and revenues beat their respective estimates. The company benefited from improving market conditions and relatively broad-based growth across its portfolio. Higher sales volumes and effective execution of strategic initiatives supported its financial performance. It highlighted continued investments in innovation, digital capabilities and its Spinnaker sales and marketing excellence program. These initiatives have strengthened MTD’s competitive position and positioned it to capitalize on emerging growth opportunities. This strong performance prompted the company to raise its 2026 guidance.
Also, the expansion of both the margins looks encouraging.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace (MEDP - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.
View the Zacks #1 Rank List
Image: Bigstock
Mettler-Toledo Stock Up on Q3 Earnings & Revenue Beat, '26 View Up
Key Takeaways
Mettler-Toledo International (MTD - Free Report) reported third-quarter 2026 adjusted earnings of $12.57 per share, which beat the Zacks Consensus Estimate by 3.8%. Adjusted earnings increased 13% from $11.15 per share a year ago.
Net sales of $1.09 billion increased 6% year over year and surpassed the Zacks Consensus Estimate by 2.3%. Improving market demand, particularly in Asia/Rest of World, supported the quarterly performance. Organic local-currency sales increased 6%, reflecting relatively broad-based growth across the company's portfolio.
Following the earnings announcement, MTD stock rose 0.1% in after-market trading yesterday.
MTD Benefits From Strong Regional Sales Momentum
On a local-currency basis, MTD's sales increased 3% in the Americas, 2% in Europe and 14% in Asia/Rest of World during the third quarter. The strong performance in Asia/Rest of World was a key contributor to overall sales growth.
On a reported basis, Americas sales increased 3% year over year, while European sales remained flat. Asia/Rest of World sales climbed 16%, highlighting the region's contribution to the company's revenue expansion.
Excluding acquisitions, organic local-currency sales increased 6% during the quarter. Organic sales growth reached 3% in the Americas and 13% in Asia/Rest of World, indicating that underlying demand supported growth beyond acquisition contributions.
MTD Expands Profitability Despite Higher Expenses
Gross profit increased to $654.22 million from $609.46 million in the prior-year quarter. Gross margin expanded 60 basis points year over year to 59.8%, reflecting improved profitability.
Research and development expenses increased to $53.61 million from $51.14 million. Selling, general and administrative expenses rose to $267.16 million from $248.39 million. Meanwhile, amortization expenses declined to $19.37 million from $20.02 million.
Adjusted operating profit increased 8% year over year to $333.45 million. Adjusted operating margin expanded 40 basis points to 30.5%, demonstrating improved operating efficiency despite higher expenses.
Mettler-Toledo Generates Solid Operating Cash Flow
As of Sept. 30, 2026, cash and cash equivalents were $52.24 million compared with $ $51.4 million as of June 30, 2025. Long-term debt declined to $1.96 billion from $2.09 billion over the same period.
Mettler-Toledo generated $308.57 million in operating cash flow during the third quarter, compared with $299.37 million in the year-ago period. Adjusted free cash flow increased to $285.15 million from $280.73 million.
Mettler-Toledo Raises 2026 Outlook and Issues 2027 Guidance
For 2026, Mettler-Toledo raised its adjusted earnings guidance to $47.70-$47.90 per share from $47.15-$47.50. The updated outlook implies earnings growth of approximately 12%. The Zacks Consensus Estimate for the metric is pegged at $47.38, implying 11% year-over-year growth.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Toledo International, Inc. Quote
The company now anticipates full-year local-currency sales growth of approximately 5%, excluding customer tariff refunds, compared with its earlier projection of 4-5%. The Zacks Consensus Estimate is pegged at $4.23 billion, implying 8.6% growth from 2025.
Management expects local-currency sales to increase approximately 5% in 2027. Adjusted earnings are projected to be between $52.50 and $53.50 per share, implying growth of approximately 10-12%. Per the Zacks Consensus Estimate, 2027 sales and EPS are projected to be $4.43 billion and $52.37, respectively.
Our Take
Mettler-Toledo posted better-than-expected third-quarter results, wherein both earnings and revenues beat their respective estimates. The company benefited from improving market conditions and relatively broad-based growth across its portfolio. Higher sales volumes and effective execution of strategic initiatives supported its financial performance. It highlighted continued investments in innovation, digital capabilities and its Spinnaker sales and marketing excellence program. These initiatives have strengthened MTD’s competitive position and positioned it to capitalize on emerging growth opportunities. This strong performance prompted the company to raise its 2026 guidance.
Also, the expansion of both the margins looks encouraging.
Zacks Rank & Stocks to Consider
MTD currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace (MEDP - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.